Bankruptcy Auction! Bid Deadline: Oct 4, 2023
DNAtrix
- - Clinical-stage biotechnology company focusing on the development of cutting edge, virus-driven immunotherapies for difficult-to-treat cancers.
- - 15 granted patents protecting the intellectual property behind drugs and Immunotherapy process in the U.S, Canada, Europe and Asia. Heavily Differentiated and patented Immunology approach with progressive drugs.
- - Significant cash flow potential both internally and through out-licensing products.
Top Therapies & Top Clinical Trial Status:
• Company Website: https://www.dnatrix.com/
For Access to Full Data Room, please complete and execute the Confidentiality Agreement/NDA posted on this website, and then email to Jolshin@AuctionAdvisors.com. Upon our receipt of the executed agreement, you will receive an invitation via email to access the SecureDocs Data room.
More Information